Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

Bibliography

• BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2001) 411:355–365.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of kinases implicated in cancer.
   Google Scholar
• HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57–70.
   PubMed Web of Science ®Google Scholar
• ZWICK E, BANGE J, ULLRICH A: Receptor tyrosine kinases as targets for anticancer drugs. Trends MM. Med. (2002) 8:17–23.
   PubMed Web of Science ®Google Scholar
• SCHLESSINGERJ, ULLRICH A: Growth factor signaling by receptor tyrosine kinases. Neuron (1992) 9:383–391.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of RTK signalling.
   Google Scholar
• HILGER RA, KREDTKE S, HEDLEY D et al.: Inhibition of ERK phosphorylation and clinical outcome in patients treated with the Raf kinase inhibitor BAY 43–9006. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 1916).
   Google Scholar
• MITCHELL DY, REID JM, PARCHMENT RE et al: Pharmacokinetics (PK) and pharmacodynamics of the oral MEK inhibitor, CI-1040, following multiple dose administration to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 320).
   Google Scholar
• LIOTTA LA, KOHN EC: The microenvironment of the tumour-host interface. Nature (2001) 411:375–379.
   PubMed Web of Science ®Google Scholar
• MAHER EA, FURNARI FB, BACHOO RIVI et al.: Malignant glioma: genetics and biology of a grave matter. Genes Dev. (2001) 15:1311–1333.
   PubMed Web of Science ®Google Scholar
• HEINRICH MC, BLANKE CD, DRUKER BJ, CORLESS CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. I Clin. Oncol (2002) 20:1692–1703.
   PubMed Web of Science ®Google Scholar
• SHIMIZU A, O'BRIEN KP, SJOBLOM Tet al.: The dermatofibrosarcoma protuberans-associated collagen type Tali platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. (1999) 59:3719–3723.
   Google Scholar
• MAURO MJ, O'DWYER M, HEINRICH MC, DRUKER BJ: STI-571: A paradigm of new agents for cancer therapeutics. Clin. Oncol. (2002) 20:325–334.
   Google Scholar
• •Good review of imatinib mesylate.
   Google Scholar
• GILLILAND DG, GRIFFIN JD: Role of FLT3 in leukemia. Curr: Opin. Hematol (2002) 9:274–281.
   Google Scholar
• BEGHINI A, LARIZZA L, CAIROLI R, MORRA E: c-Kit activating mutations and mast cell proliferation in human leukemia. Blood(1998) 92:701–703.
   PubMed Web of Science ®Google Scholar
• REILLY IT: Class III receptor tyrosine kinases: role in leukaemogenesis. Br. J. Haematol. (2002) 116:744–757.
   PubMed Web of Science ®Google Scholar
• KLINT P, CLAESSON-WELSH L: Signal transduction by fibroblast growth factor receptors. Front. Biosci. (1999) 4:165–177.
   PubMedGoogle Scholar
• GUASCH G, OLLENDORFF V, BORG J-P, BIRNBAUM D, PEBUSQUE M-J: 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6,8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways. MM. Cell. Biol. (2001) 21:8129–8142.
   Web of Science ®Google Scholar
• POPOVICI C, ADELAIDE J, OLLENDORFF V et al.: Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13) (p12;q12) . Proc. Nati Acad. Sci. USA (1998) 95:5712–5717.
   PubMed Web of Science ®Google Scholar
• SOHAL J, CHASE A, MOULD S et al.: Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer (2001) 32:155–163.
   PubMed Web of Science ®Google Scholar
• OLLENDORFF V, GUASCH G, ISNARDON D et al.: Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation. J. Biol. Chem. (1999) 274:26922–26930.
   PubMed Web of Science ®Google Scholar
• REITER A, SOHAL J, KULKARNI S et al: Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8,13)(p11;q12) myeloproliferative syndrome. Blood (1998) 92: 1735-1742.
   Google Scholar
• TOMASSON MH, WILLIAMS IR, HASSERJIAN R et al: TEL/PDGFI3R induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood(1999) 93: 1707-1714.
   Google Scholar
• HIDALGO M, ERLICHMAN C, ROWINSKY EK et al: Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 65).
   Google Scholar
• KRIS MG, NATALE RB, HERBST RS et al: A phase II trial of ZD1839 CIressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regiments (IDEAL2). Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 1166).
   Google Scholar
• FUKUOKA M, YANO S, GIACCONE G et al: Final results from a phase II trial of ZD1839 (Iressa') for patients with advanced non-small-cell lung cancer (IDEAL1). Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 1188).
   Google Scholar
• KIES MS, ARQUETTE M, NABELL L et al.: Final report of the efficacy and safety of the anti-epidermal growth factor antibody, cetuximab (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 925).
   Google Scholar
• CHRISTENSEN JG, SCHRECK RE, CHAN E et al.: High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGER) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin. Canc. Res. (2001) 7:4230–4238.
   PubMed Web of Science ®Google Scholar
• ANIDO J, ALBANNEL J, ROJO F et al.: ZD1839 (Iressa'), a specific epidermal growth factor receptor (EGER) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HERZ overexpressing breast cancer cells. Proc. Am. Assoc. Cancer Res. (2002) 43:783.
   Google Scholar
• HERBST RS, MADDOX AM, ROTHENBERG ML et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a Phase I Trial. J. Clin. Oncol. (2002) 20:3815–3825.
   PubMed Web of Science ®Google Scholar
• ••Phase I results with ZD1839.
   Google Scholar
• WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60:2178–2189.
   PubMed Web of Science ®Google Scholar
• YUNG WKA, FRIEDMAN H, JACKSON E et al.: A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 315).
   Google Scholar
• DREVS J, SCHMIDT-GERSBACH GI,MROSS K et al.: Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in two clinical phase I trials. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 337).
   Google Scholar
• THOMAS A, MORGAN B, DREVS J et al.: Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 Phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20 (Abstract 279).
   Google Scholar
• BERGSLAND EK, FEHRENBACHER L, NOVOTNY W et al: Bevacizumab (BV) + chemotherapy (CT) may improve survival in metastatic colorectal cancer (MCRC) subjects with unfavorable prognostic indicators. Proc. Am. Soc. Clin. Oncol. (2001) 20 (Abstract 2247).
   Google Scholar
• YANG JC, HAWORTH L, STEINBERG SM, ROSENBERG SA, NOVOTNY W: A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 15).
   Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al: Development of a preclinical pharmacokinetic/pharmacodynamic relationship for the angiogenesis inhibitor SU11248, a selective inhibitor of VEGF and PDGF receptor tyrosine kinases in clinical development. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 94).
   Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al: In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Canc. Res. (In press).
   Google Scholar
• ••Determination of the predinicalpharmacokinetic/pharmacodynamic relationship for SU11248.
   Google Scholar
• ROBERTS WG, JANI J, BEEBE J et al.: Preclinical development of CP-547,632, a novel VEGFR-2 inhibitor for cancer therapy. Proc. Am. Soc. Gin. Oncol. (2002) 21 (Abstract 473).
   Google Scholar
• HU-LOWE D, HALLIN M, FEELEY R et al.: Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736. Proc. Am. Assoc. Cancer Res. (2002) 43:1082.
   Google Scholar
• HU-LOWE D, HELLER D, BREKKEN J et al.: Pharmacological activities of AG013736, a small molecule inhibitor of VEGF/PDGR receptor tyrosine kinase. Proc. Am. Assoc. Cancer Res. (2002) 43:1082.
   Google Scholar
• ABRAMS TJ, LEE LB, MURRAY LJ, MENDEL DB, CHERRINGTON JM: Inhibition of Kit-positive SCLC growth by SU11248, a novel tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res. (2002) 43:337.
   Google Scholar
• SEBTI SM, HAMILTON AD: Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene (2000) 19:6566–6573.
   PubMed Web of Science ®Google Scholar
• FERRARA N: VEGF: an update on biological and therapeutic aspects. Curr. Opin. Biotech. (2000) 11:617–624.
   PubMed Web of Science ®Google Scholar
• LINDAHL P, JOHANSSON BR, LEVEEN P, BETSHOLTZ C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (1997) 277:242–245.
   PubMed Web of Science ®Google Scholar
• CHERRINGTON JM, STRAWN LM, SHAWVER LK: New paradigms for the treatment of cancer; the role of anti-angiogenesis agents. In: Advances in Cancer Research. G Klein, GF van de Woude (Eds), Academic Press, San Diego, CA, USA (2000):1–38.
   Google Scholar
• LAIRD AD, CHRISTENSEN JG, LI G et al: 5U6668 inhibits Flk-1/KDR and PDGFRI3 in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB (2002) 16:681–690.
   PubMed Web of Science ®Google Scholar
• COHEN MH, WILLIAMS G, JOHNSON JR et al.: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Gin. Cancer Res. (2002) 8:935–942.
   Web of Science ®Google Scholar
• ••FDA approval summary for imatinibmesylate in CML.
   Google Scholar
• DAGHER R, COHEN M, WILLIAMS G et al.: Approval summary: imatinib mesylate in the treatment of metastatic and/or resectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. (2002) 8:3034–3038.
   PubMed Web of Science ®Google Scholar
• ••FDA approval summary for imatinibmesylate in GIST.
   Google Scholar
• APPERLEY JF, GARDEMBAS M, MELO JV et al.: Response to Imatinib Mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor 13. N Engl. J. Med. (2002) 347:481–487.
   PubMed Web of Science ®Google Scholar
• ••Dramatic responses to imatinib mesylatedocumented in several patients with activating mutations of PDGFR-13.
   Google Scholar
• RUBIN BP, SCHUETZE SM, EARY JF et al.: Molecular targeting of platelet-derived growth factor B by Imatinib Mesylate in a patient with metastatic Dermatofibrosarcoma protuberans. Clin. Oncol. (2002) 20:3586–3591.
   Web of Science ®Google Scholar
• MAKI RG, AWAN RA, DIXON RH, JHANWAR S, ANTONESCU CR: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from Dermatofibrosarcoma protuberans. Int. Cancer (2002) 100:623–626.
   PubMed Web of Science ®Google Scholar
• JOHNSON BE, FISHER B, FISHER T et al.: Phase II study of 5T15 71 (GleevecTM) for patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 1171).
   Google Scholar
• HADDAD R, LIPSON KE, WEBB CP: Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res. (2001) 21:4243–4252.
   PubMed Web of Science ®Google Scholar
• DANILKOVITCH-MIAGKOVA A, ZBAR B: Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.' Clin. Invest. (2002) 109:863–867.
   Google Scholar
• HOLASH J, WIEGAND SJ, YANCOPOULOS GD: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene (1999) 18:5356–5362.
   PubMed Web of Science ®Google Scholar
• ARNOLD LD, DIXON R, TALANIAN R et al.: Molecular interactions in crystal structures of potent inhibitors bound to the kinase domain of Tie-2. Proc. Am. Assoc. Cancer Res. (2002) 43:848.
   Google Scholar
• WISHART N, ARNOLD LD, BARLOZZARI T et al.: Structure activity relationships for a novel series of pyrrolo[2,3-d]pyrimidine Tie-2 inhibitors. Proc. Am. Assoc. Cancer Res. (2002) 43:848.
   Google Scholar
• QIAN X-D, GEORGE JS, MOSKEY MD et al.: Inhibition of angiogenesis by BSF 466895 (A-422885.66), a potent and selective low molecular weight Tie-2 kinase inhibitor. Proc. Am. Assoc. Cancer Res. (2002) 43:1080.
   Google Scholar
• THURSTON G, RUDGE JS, IOFFE E et al.: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. (2000) 6:460–463.
   PubMed Web of Science ®Google Scholar
• IRBY RB, YEATMAN TJ: Role of Src expression and activation in human cancers. Oncogene (2000) 19:5636–5642.
   PubMed Web of Science ®Google Scholar
• BISCARDI JS, TICE DA, PARSONS SJ: c-Src, receptor tyrosine kinases, and human cancer. Adv. Cancer Res. (1999) 76:61–119.
   PubMed Web of Science ®Google Scholar
• BELSCHES-JABLONSKI AP, BISCARDI JS, PEAVY DR et al.: Src family kinases and HERZ interactions in human breast cancer cell growth and survival. Oncogene (2001) 20:1465–1475.
   PubMed Web of Science ®Google Scholar
• ALLGAYER H, BOYD DD, HEISS MM et al.: Activation of Src kinase in primary colorectal carcinoma. An indicator of poor clinical prognosis. Cancer (2002) 94:344–351.
   Google Scholar
• KANE LP, LIN J, WEISS A: Signal transduction by the TCR for antigen. Curr. Opin. Immunol. (2000) 12:242–249.
   PubMed Web of Science ®Google Scholar
• BLAKE RA, BROOME MA, LIU X et al.: 5U6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell. Biol. (2000) 20:9019–9027.
   Google Scholar
• MISSBACH M, JESCHKE M, FEYEN J et al.: A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone (1999) 24:437–449.
   PubMed Web of Science ®Google Scholar
• SHAKESPEARE W, YANG M, BOHACEK R et al.: Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Nati Acad. Sci. USA (2000) 97:9373–9378.
   PubMed Web of Science ®Google Scholar
• VIOLETTE SM, GUAN W, BARTLETT C et al.: Bone-targeted Src 5H2 inhibitors block Src cellular activity and osteoclast-mediated resorption. Bone (2001) 28:54–64.
   PubMed Web of Science ®Google Scholar
• IRBY RB, MAO W, COPPOLA D et al.: Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. (1999) 21:187–190.
   PubMed Web of Science ®Google Scholar
• REIFENBERGER G, ICHIMURA K, REIFENBERGER J et al.: Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res. (1996) 56:5141–5145.
   PubMed Web of Science ®Google Scholar
• GAFFEY MJ, FRIERSON HF Jr, WILLIAMS ME: Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. Modern Pathology (1993) 6:654–659.
   PubMed Web of Science ®Google Scholar
• REITER RE, SATO I, THOMAS G et al.: Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer (2000) 27:95–103.
   PubMed Web of Science ®Google Scholar
• PEGRAM MD, PAULETTI G, SLAMON DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. (1998) 52:65–77.
   PubMed Web of Science ®Google Scholar
• DAVIES H, BIGNELL GR, COX C et al.: Mutations of the BRAF gene in human cancer. Nature (2002) 417:949–954.
   PubMed Web of Science ®Google Scholar
• MACDONALD TJ, BROWN KM, LAFLEUR B et al.: Expression profiling of medulloblastomas: PDGFRA and the RAS/ MAPK pathway as therapeutic targets for metastatic disease. Nat. Genet. (2001) 29:143–152.
   PubMed Web of Science ®Google Scholar
• •Identification of a primary tumour transcript expression fingerprint' diagnostic for metastatic medulloblastoma.
   Google Scholar
• PETRICOIN EF, ARDEKANI AM, HITT BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 359:572–577.
   PubMed Web of Science ®Google Scholar
• •Identification of a serum proteomic fingerprint' diagnostic for ovarian cancer.
   Google Scholar
• ALBANELL J, ROJO F, AVERBUCH S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition.' Clin. Oncol. (2002) 20:110–124.
   Google Scholar
• ••Pioneering biomarker study for ZD1839in surrogate tissue (skin).
   Google Scholar
• HU-LOWE D, HELLER D, BREKKEN J et al.: Pharmacological activities of AG013736, a small molecule inhibitor of VEGF/PDGF receptor tyrosine kinases. Proc. Am. Assoc. Cancer Res. (2002).
   Google Scholar
• MENDEL DB, LAIRD DA, SMOLICH B et al.: Development of 5U5416, a Selective Small Molecule Inhibitor of VEGF Receptor Tyrosine Kinase Activity, as an Anti-Angiogenesis Agent. Anti-Cancer Drug Design (2000) 15:29–41.
   PubMedGoogle Scholar
• STOPECK A, SHELDON M, VAHEDIAN M et al.: Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, 5U5416, in Patients with Advanced Malignancies. Clin. Cancer Res. (2002) 8:2798–2805.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL, JOHNSON DH: Tyrosine kinase inhibitors-ZD1839 (Iressa). Carr. Opin. Oncol. (2001) 13:491–498.
   PubMed Web of Science ®Google Scholar
• KIES MS, ARQUETTE M, NABELL L et al.: Final report of the efficacy and safety of the anti-epidermal growth factor antibody, cetuximab (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc. Am. Soc. Clin. Oncology(2002) 21:232a (Abstract 925).
   Google Scholar
• STRUMBERG D, BAUER RJ, MOELLERJG et al.: Final results of a phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43–9006 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 121).
   Google Scholar
• MOORE M, HIRTE H, OZA A et al: Phase I study of the Raf-1 kinase inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. Proc. Am. Soc. Clin. Omni (2002) 21 (Abstract 1816).
   Google Scholar
• LORUSSO P, ADJEI AA, MEYER MB et al.: A phase I clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 321).
   Google Scholar
• GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Clin. Oncol (2001) 19:843–850.
   Web of Science ®Google Scholar
• LI B, OGASAWARA AK, YANG R et al.: KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension (2002) 39:1095–1100.
   PubMed Web of Science ®Google Scholar
• EPPLER SM, COMBS DL, HENRY TD et al.: A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol flier: (2002) 72:20–32.
   Web of Science ®Google Scholar
• GORRE ME, SAWYERS CL: Molecular mechanisms of resistance to 5TI571 in chronic myeloid leukemia. Curr: Opin. Hematol (2002) 9:303–307.
   Google Scholar
• •Incisive review of mechanisms underlying resistance to irnatinib mesylate in CML patients.
   Google Scholar
• BLAGOSKLONNY MV: STI-571 must select for drug-resistant cells but no cell breathes fire out of its nostrils like a dragon'. Leukemia (2002) 16:570–572.
   PubMed Web of Science ®Google Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293:876–880.
   PubMed Web of Science ®Google Scholar
• ROCHE-LESTIENNE C, SOENEN-CORNU V, GRARDEL-DUFLOS N et al: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood (2002) 100:1014–1018.
   PubMed Web of Science ®Google Scholar
• GALE NW, YANCOPOULOS GD: Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. (1999) 13:1055–1066.
   PubMed Web of Science ®Google Scholar
• LUTTUN A, TJVVA M, MOONS Let al.: Revascularization of ischemic tissues by P1GF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Fltl. Nat. Med. (2002) 8:831–840.
   Google Scholar
• AGUAYO A, MANSHOURI T, O'BRIEN S et al.: Clinical relevance of Flt1 and Tie], angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leukemia Res. (2001) 25:279–285.
   Google Scholar
• FERRAJOLI A, MANSHOURI T, ESTROV Z et al.: High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin. Canc. Res. (2001) 7:795–799.
   PubMed Web of Science ®Google Scholar
• FOSS B, ULVESTAD E, BRUSERUD 0: Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur. Haematol (2001) 67:267–278.
   PubMed Web of Science ®Google Scholar
• BENJAMIN LE, HEMO I, KESHET E: A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF- B and VEGE Development (1998) 125:1591–1598.
   Google Scholar
• CHESI M, NARDINI E, LIM RSC et al.: The t(4,14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood (1998) 92:3025–3034.
   PubMed Web of Science ®Google Scholar
• CHESI M, BERGSAGEL PL, KUEHL WM: The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. Curr: Opin. Hematol (2002) 9:288–293.
   Google Scholar
• CHESI M, NARDINI E, BRENTS LA et al.: Frequent translocation t(4,14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. (1997) 16:260.
   Google Scholar
• LIZ, ZHU YX, PLOWRIGHT EE et al: The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood (2001) 97:2413–2419.
   PubMed Web of Science ®Google Scholar
• WAKELING AE, GUY SP, WOODBURN JR et al: ZD1839 (Iressa): An Orally Active Inhibitor of Epidermal Growth Factor Signaling with Potential for Cancer Therapy. Cancer Res. (2002) 62:5749–5754.
   PubMed Web of Science ®Google Scholar
• RATAIN MJ, GEORGE CM, JANISCH L et al.: Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 2115).
   Google Scholar
• FORERO L, PATNAIK A, HAMMOND LA et al.: Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor (EGER) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 1908).
   Google Scholar
• FOROUZESH B, HIDALGO M, TAKIMOTO C et al.: Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc. Am. Soc. Clin. Omni (2002) 21 (Abstract 81).
   Google Scholar
• ROGERS LR, KAELINE W, NADLER P, SHIELDS AF, LORUSSO P: Response of cerebellar hemangioblastomas associated with von Hippel-Lindau disease to OSI-774 (Tarceval . Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 2111).
   Google Scholar
• RINEHART JJ, WILDING G, WILLSON J et al.: A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Omni (2002) 21 (Abstract 41).
   Google Scholar
• ZINNER RG, DONATO NJ, NEMUNAITIS JJ et al: Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor, CI-1033. Proc. Am. Soc. Clin. Omni (2002) 21 (Abstract 58).
   Google Scholar
• OLSON SC, BAKER L, CUNNINGHAM CC et al.: A population pharmacokinetic (PPK) analysis of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 361).
   Google Scholar
• HOEKSTRA R, DUMEZ H, VAN OOSTEROM AT et al.: A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGER) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 340).
   Google Scholar
• DUMEZ H, HOEKSTRA R, ESKENS F et al.: A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 341).
   Google Scholar
• XIA W, MULLIN RJ, KEITH BR et at Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21:6255–6263.
   PubMed Web of Science ®Google Scholar
• DeSIMONE PA, BENCE AK, ANDERSON EB et al.: A phase I study to investigate the safety, tolerability and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 375).
   Google Scholar
• HURWITZ H, HOLDEN SN, ECKHARDT SG et al.: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc. AM. Soc. Clin. Oncol. (2002) 21 (Abstract 383).
   Google Scholar
• VON MEHREN M, BLANKE C, JOENSUU H et al.: High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GIST). Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 1608).
   Google Scholar
• HEINRICH MC, CORLESS CL, BLANKE C et al.: KIT mutational status predicts clinical response to 5TI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 6).
   Google Scholar
• VAN DEN ABBEELE AD, BADAWI RD, CLICHE J-P et al.: 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 1610).
   Google Scholar
• LAIRD AD, VAJKOCZY P, SHAWVER LK et al.: 5U6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. (2000) 60:4152–4160.
   PubMed Web of Science ®Google Scholar
• BRITTEN CD, ROSEN LS, KABBINAVAR F et al.: Phase I trial of 5U6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 1922).
   Google Scholar
• WEISBERG E, BOULTON C, LOUISE K et al.: Inhibition of mutant FLT3 receptors in leukemia cells by a small molecule tyrosine kinase inhibitor. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 16).
   Google Scholar
• FABBRO D, RUETZ S, BODIS S et PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anti-cancer Drug Des. (2000) 15:17–28.
   PubMedGoogle Scholar
• TOLCHER AW, O'LEARY JJ, DEBONO JS et al.: A phase land biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 16).
   Google Scholar
• GEORGE DJ, DIONNE CA, JANI J et Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. (1999) 59:2395–2401.
   PubMed Web of Science ®Google Scholar
• LEVIS M, ALLEBACH J, TSE K-F et al.: A Flt3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells M vitro and in vivo. Blood (2002) 99:3885–3891.
   PubMed Web of Science ®Google Scholar
• RUGGERI B, SINGH J, HUDKINS R et al.: CEP-7055: An orally-active VEGF-R kinase inhibitor with potent anti-angiogenic activity and anti-tumor efficacy against human tumor xenograft growth. Proc. Am. Assoc. Cancer Res. (2002) 43:1080.
   Google Scholar
• JONES-BOLIN S, HUNTER K, ZHAO H, RUGGERI B: The effects of the orally-active VEGF-R kinase inhibitor, CEP-7055, on primary tumor growth and metastatic profile in orthotopic models of human pancreatic ductal carcinoma and murine renal carcinoma (RENCA) in mice. Proc. Am. Assoc. Cancer Res. (2002) 43:524.
   Google Scholar
• YU J, APATIRA M, LI J et at CT53518, a specific Flt3 kinase inhibitor selectively blocks mitogenic and survival signaling pathways and induces apoptosis in human AML cells that harbor a Flt3/ITD mutation. Proc. Am. Assoc. Cancer Res. (2002) 43 (Abstract LB27).
   Google Scholar